Related Experiment Video

Updated: Jun 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Angiogenesis inhibitors in the treatment of prostate cancer

Paul G Kluetz1, William D Figg, William L Dahut

  • 1National Cancer Institute, Medical Oncology Branch, Building 10, Room 12N226, 9000 Rockville Pike Bethesda, MD 20892, USA.

Expert Opinion on Pharmacotherapy
|January 22, 2010
PubMed
Abstract

Insights

New antiangiogenic therapies are crucial for treating metastatic castrate-resistant prostate cancer (mCRPC) as current treatments lack durability. Research explores novel compounds targeting tumor angiogenesis for improved patient outcomes.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Prostate cancer is a leading non-cutaneous malignancy in U.S. men.
  • Current treatments like docetaxel and prednisone offer limited durability for metastatic castrate-resistant prostate cancer (mCRPC).
  • There is a critical need for novel therapeutic strategies to overcome treatment resistance.

Purpose of the Study:

  • To review the development of antiangiogenic compounds for prostate cancer.
  • To discuss agents targeting tumor angiogenesis, including VEGF inhibitors and vascular-disrupting agents.
  • To provide an understanding of the role of angiogenesis in prostate cancer progression.

Main Methods:

  • Review of literature on antiangiogenic agents in prostate cancer.
  • Discussion of compounds targeting VEGF, its receptors, and downstream signaling pathways.
  • Inclusion of immunomodulatory drugs and vascular-disrupting agents.

Main Results:

  • Angiogenesis plays a significant role in prostate cancer growth and metastasis.
  • Various antiangiogenic drugs are in development, targeting multiple points in the angiogenesis pathway.
  • Early-phase clinical trials are evaluating these agents alone and in combination.

Conclusions:

  • Antiangiogenic agents represent a promising therapeutic avenue for prostate cancer.
  • Combination therapy with antiangiogenic compounds may enhance treatment efficacy.
  • Continued investigation into novel angiogenesis targets is essential for advancing prostate cancer treatment.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...